[
  {
    "ts": null,
    "headline": "Why AbbVie Stock Cruised to an Almost 6% Gain Today",
    "summary": "A new expansion project and a win for a peer pharmaceutical company were attracting investors to the shares.",
    "url": "https://finnhub.io/api/news?id=f8c4bea7262ee055e429a21acea1ffad9d4371adaac7910106a851030e783ec9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759358163,
      "headline": "Why AbbVie Stock Cruised to an Almost 6% Gain Today",
      "id": 136952190,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A new expansion project and a win for a peer pharmaceutical company were attracting investors to the shares.",
      "url": "https://finnhub.io/api/news?id=f8c4bea7262ee055e429a21acea1ffad9d4371adaac7910106a851030e783ec9"
    }
  },
  {
    "ts": null,
    "headline": "Why AbbVie (ABBV) Stock Is Trading Up Today",
    "summary": "Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 5.2% in the afternoon session after the company submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for its drug candidate pivekimab sunirine. The company is developing the molecule as a potential treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and highly aggressive blood cancer, as well as acute myeloid leukemia (AML). Investor optimism was further bolstered by AbbVie",
    "url": "https://finnhub.io/api/news?id=0bca266385a251b952a1b7183256ddbcec174ee33956b13388248144a702acf7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759348870,
      "headline": "Why AbbVie (ABBV) Stock Is Trading Up Today",
      "id": 136952020,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 5.2% in the afternoon session after the company submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for its drug candidate pivekimab sunirine. The company is developing the molecule as a potential treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and highly aggressive blood cancer, as well as acute myeloid leukemia (AML). Investor optimism was further bolstered by AbbVie",
      "url": "https://finnhub.io/api/news?id=0bca266385a251b952a1b7183256ddbcec174ee33956b13388248144a702acf7"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Dividend Aristocrat Stocks to Invest in Right Now. AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that manufactures and markets innovative medicines. The demand for drugs is so stable that the industry is considered highly defensive, with little economic exposure. Even in recessions, doctors continue to […]",
    "url": "https://finnhub.io/api/news?id=c7b57975b3cd1168a22a79f462f5aa86252ce9c779c092f273de6fc396252491",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759341444,
      "headline": "AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability",
      "id": 136952192,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Dividend Aristocrat Stocks to Invest in Right Now. AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that manufactures and markets innovative medicines. The demand for drugs is so stable that the industry is considered highly defensive, with little economic exposure. Even in recessions, doctors continue to […]",
      "url": "https://finnhub.io/api/news?id=c7b57975b3cd1168a22a79f462f5aa86252ce9c779c092f273de6fc396252491"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=9b65a1d687795754f369478a86dca1d27922bcd249f04fe321704ffa6ab53d3e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759336260,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 136995801,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=9b65a1d687795754f369478a86dca1d27922bcd249f04fe321704ffa6ab53d3e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie breaks ground on $70m US biologics site amid Trump pressure",
    "summary": "The bioresearch centre expansion is part of AbbVie’s wider ploy to bolster its US operations.",
    "url": "https://finnhub.io/api/news?id=a2a72255885206743b94ddbb778b47fb4df8560a3b03418a854e7ac25b5d059a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759333023,
      "headline": "AbbVie breaks ground on $70m US biologics site amid Trump pressure",
      "id": 136947256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The bioresearch centre expansion is part of AbbVie’s wider ploy to bolster its US operations.",
      "url": "https://finnhub.io/api/news?id=a2a72255885206743b94ddbb778b47fb4df8560a3b03418a854e7ac25b5d059a"
    }
  },
  {
    "ts": null,
    "headline": "Atai Life Sciences: Still A Decent Prospect - But Only Just",
    "summary": "Discover Atai Life Sciences N.V.'s 275% YTD surge, driven by innovative psychedelic therapies for TRD. Click for my ATAI stock update and why I remain bullish.",
    "url": "https://finnhub.io/api/news?id=9c755a383bbfaacff6cb67ac6ad31aa2f8a7204fc289f4e3eeeec08beec68679",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759329649,
      "headline": "Atai Life Sciences: Still A Decent Prospect - But Only Just",
      "id": 136948818,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2055023486/image_2055023486.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover Atai Life Sciences N.V.'s 275% YTD surge, driven by innovative psychedelic therapies for TRD. Click for my ATAI stock update and why I remain bullish.",
      "url": "https://finnhub.io/api/news?id=9c755a383bbfaacff6cb67ac6ad31aa2f8a7204fc289f4e3eeeec08beec68679"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Is Just What the Doctor Ordered",
    "summary": "AbbVie (ABBV) stands out after its Allergan acquisition thanks to a transformed portfolio and higher long-term growth prospects. ABBV is trading at fresh all-time highs. Shares have a 100% Barchart “Buy” opinion and are trading above key moving averages. Analyst and investor sentiment is positive, with most major firms rating...",
    "url": "https://finnhub.io/api/news?id=aa6d9d49e9e6cd9e1eae9d6fa349067d1ad93429477f15df4c1c3bb5e4194bd4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759328102,
      "headline": "AbbVie Stock Is Just What the Doctor Ordered",
      "id": 136952193,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) stands out after its Allergan acquisition thanks to a transformed portfolio and higher long-term growth prospects. ABBV is trading at fresh all-time highs. Shares have a 100% Barchart “Buy” opinion and are trading above key moving averages. Analyst and investor sentiment is positive, with most major firms rating...",
      "url": "https://finnhub.io/api/news?id=aa6d9d49e9e6cd9e1eae9d6fa349067d1ad93429477f15df4c1c3bb5e4194bd4"
    }
  },
  {
    "ts": null,
    "headline": "2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi",
    "summary": "The global dermatology market is driven by increasing skin disorder prevalence, aging demographics, and technological innovations like teledermatology and nanotechnology. The influence of social media, emerging middle-class markets, and advancements in biologics and transdermal patches also present significant growth opportunities.Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The \"Dermatology Treatment and Care Market With Impact Analysis of US Tariffs (2025 Edition)\" report has been added to Resear",
    "url": "https://finnhub.io/api/news?id=d7e68261cb613c26641b6be3775103fee153cf86174ed801f8f74c35996a6fb1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759325460,
      "headline": "2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi",
      "id": 136947247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The global dermatology market is driven by increasing skin disorder prevalence, aging demographics, and technological innovations like teledermatology and nanotechnology. The influence of social media, emerging middle-class markets, and advancements in biologics and transdermal patches also present significant growth opportunities.Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The \"Dermatology Treatment and Care Market With Impact Analysis of US Tariffs (2025 Edition)\" report has been added to Resear",
      "url": "https://finnhub.io/api/news?id=d7e68261cb613c26641b6be3775103fee153cf86174ed801f8f74c35996a6fb1"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Oct 1, 2025",
    "summary": "Companies in The News Are: LW, UNFI, PRGS, ABBV",
    "url": "https://finnhub.io/api/news?id=df154390d6f0b602938a1b59ce5b273489189fe3eb58d4929baa48886f7b1133",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759324920,
      "headline": "Company News for Oct 1, 2025",
      "id": 136947258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Companies in The News Are: LW, UNFI, PRGS, ABBV",
      "url": "https://finnhub.io/api/news?id=df154390d6f0b602938a1b59ce5b273489189fe3eb58d4929baa48886f7b1133"
    }
  },
  {
    "ts": null,
    "headline": "Natrelle® Awarded Supplier Agreement from Vizient",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that Natrelle® has been named a supplier by Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company. This agreement connects Natrelle® to Vizient's extensive network of academic medical centers, community hospitals, integrated delivery networks, and non-acute care providers, representing more than half of U.S. healthcare organizations.",
    "url": "https://finnhub.io/api/news?id=b832c7fc8b73140313f5571b01fd4caf429ccd984c1c5a8fb2e6067be0a5858f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759320000,
      "headline": "Natrelle® Awarded Supplier Agreement from Vizient",
      "id": 136947259,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that Natrelle® has been named a supplier by Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company. This agreement connects Natrelle® to Vizient's extensive network of academic medical centers, community hospitals, integrated delivery networks, and non-acute care providers, representing more than half of U.S. healthcare organizations.",
      "url": "https://finnhub.io/api/news?id=b832c7fc8b73140313f5571b01fd4caf429ccd984c1c5a8fb2e6067be0a5858f"
    }
  },
  {
    "ts": null,
    "headline": "Presbyopia Market Research Report 2025-2035 | FDA-Approved Eye Drops, Advanced IOLs and Personalized Medicine Drive Global Growth Amid Aging Population",
    "summary": "The global presbyopia market is rapidly expanding, driven by a growing aging population and advancements in diagnostic and treatment options. Presbyopia, an age-related vision condition affecting the eye's ability to focus on nearby objects, is typically diagnosed through comprehensive eye exams and advanced imaging techniques like OCT. The market is witnessing significant growth due to increased awareness, with innovations in non-invasive treatments such as FDA-approved eye drops and corrective",
    "url": "https://finnhub.io/api/news?id=3d4a8866c20010797e2f27901f585b224ec3fe1dc12cdaefb94bf461d065e013",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759313820,
      "headline": "Presbyopia Market Research Report 2025-2035 | FDA-Approved Eye Drops, Advanced IOLs and Personalized Medicine Drive Global Growth Amid Aging Population",
      "id": 136944068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The global presbyopia market is rapidly expanding, driven by a growing aging population and advancements in diagnostic and treatment options. Presbyopia, an age-related vision condition affecting the eye's ability to focus on nearby objects, is typically diagnosed through comprehensive eye exams and advanced imaging techniques like OCT. The market is witnessing significant growth due to increased awareness, with innovations in non-invasive treatments such as FDA-approved eye drops and corrective",
      "url": "https://finnhub.io/api/news?id=3d4a8866c20010797e2f27901f585b224ec3fe1dc12cdaefb94bf461d065e013"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers, Takeda to pool data for AI-based drug discovery",
    "summary": "(Reuters) -Bristol Myers Squibb, Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and development.  The companies are joining a consortium that includes AbbVie and Johnson & Johnson , and will contribute data from several thousand experimentally determined protein–small molecule structures to train an AI model called OpenFold3, life sciences company Apheris said on Wednesday.  The initiative is based on a federated data sharing model, which enables collaboration without exposing sensitive data.",
    "url": "https://finnhub.io/api/news?id=56830a56a9854acb3cb037344cff517e0b1fde231c888d3be6c857c39e534905",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759311087,
      "headline": "Bristol Myers, Takeda to pool data for AI-based drug discovery",
      "id": 136944048,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "(Reuters) -Bristol Myers Squibb, Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and development.  The companies are joining a consortium that includes AbbVie and Johnson & Johnson , and will contribute data from several thousand experimentally determined protein–small molecule structures to train an AI model called OpenFold3, life sciences company Apheris said on Wednesday.  The initiative is based on a federated data sharing model, which enables collaboration without exposing sensitive data.",
      "url": "https://finnhub.io/api/news?id=56830a56a9854acb3cb037344cff517e0b1fde231c888d3be6c857c39e534905"
    }
  },
  {
    "ts": null,
    "headline": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
    "summary": "If you are looking for dividend stocks that can provide a reliable, long-term income stream, consider buying AbbVie, Coca-Cola, and Chevron.",
    "url": "https://finnhub.io/api/news?id=fea9168779b83f638a5a3df9c9db7d3bbc24f5ef67ae8976a2260052493b772d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759310700,
      "headline": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
      "id": 136944070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If you are looking for dividend stocks that can provide a reliable, long-term income stream, consider buying AbbVie, Coca-Cola, and Chevron.",
      "url": "https://finnhub.io/api/news?id=fea9168779b83f638a5a3df9c9db7d3bbc24f5ef67ae8976a2260052493b772d"
    }
  }
]